Epigallocatechin Gallate Alleviated Methotrexate-Induced Nephrotoxicity in Rats

Document Type : Original Article

Authors

1 Department of Biochemistry and Molecular Biology, Veterinary Medicine, Mansoura University

2 Department of Biochemitry nd Molecular Biology, Veterinary Medicine, Mansoura University

3 Department of Biochemistry

Abstract

Long-term usage of methotrexate drugs caused adverse reactions in a variety of organs, including stomach, intestine, kidney, liver, lung, bone marrow, brain, and testis. The current research aimed to ascertain the beneficial effects of epigallocatechin gallate, a biologically antioxidant polyphenol flavonoid, on methotrexate-induced nephrotoxicity in rats. There were four male rats groups (n=10): Control group, EGCG group 100 mg/kg b.wt. three times a week, MTX group 20 mg/kg b.wt. (i/p) once a week, and MTX + EGCG group. Serum creatinine, Blood urea nitrogen, Cystatin-C, Neutrophil gelatinase-associated lipocalin, and oxidative stress markers were estimated. Additionally, histopathological changes were examined by hematoxylin and eosin staining (H and E), and gene expression of the interleukin-1 beta and tumor necrosis factor alpha-1 were examined using quantitative real-time PCR. Data analysis recorded a notable amelioration of oxidative stress in groups that supplemented with EGCG comparing MTX-treated group as confirmed by lowering malondialdehyde and nitric oxide contents and elevation of superoxide dismutase and catalase activities in kidney tissue homogenate and returned to the basal levels of the control group. EGCG enhanced renal function parameters compared to the MTX-treated group (p<0.05). Also, histopathological examination confirmed the protective effect of EGCG against MTX. Epigallocatechin gallate administration as a natural antioxidant markedly decreased methotrexate-induced nephrotoxicity due to its anti-cancer, anti-inflammatory, and antioxidant impacts on impairment of oxidative stress and improving kidney function.

Keywords

Main Subjects



Articles in Press, Accepted Manuscript
Available Online from 08 January 2025
  • Receive Date: 05 August 2024
  • Revise Date: 24 December 2024
  • Accept Date: 24 December 2024